NASDAQ: BIVIBiovie Inc Stock
$0.49+0.01 (+2.08%)
Updated Apr 23, 2024
BIVI Price
$0.49
Fair Value Price
$0.16
Market Cap
$19.62M
52 Week Low
$0.45
52 Week High
$8.69
P/E
-0.42x
P/B
2.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.87
Operating Cash Flow
-$41M
Beta
1.25
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BIVI Overview
BioVie Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes drug therapies. Its lead product, BIV201, is a drug approved in 40 countries to treat related complications from liver cirrhosis. BioVie was incorporated in 2013 and is based in Santa Monica, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIVI ($0.49) is overvalued by 217.03% relative to our estimate of its Fair Value price of $0.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BIVI ($0.49) is not significantly undervalued (217.03%) relative to our estimate of its Fair Value price of $0.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIVI due diligence checks available for Premium users.
Be the first to know about important BIVI news, forecast changes, insider trades & much more!
BIVI News
Valuation
BIVI fair value
Fair Value of BIVI stock based on Discounted Cash Flow (DCF)
Price
$0.49
Fair Value
$0.16
Overvalued by
215.74%
BIVI ($0.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIVI ($0.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIVI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
16.46x
Market
41.92x
BIVI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.62x
Industry
5.93x
BIVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIVI's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.4M
Profit Margin
0%
BIVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.5M
Liabilities
$14.0M
Debt to equity
1.87
BIVI's short-term assets ($20.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIVI's short-term assets ($20.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIVI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
$0.0
Financing
$4.9M
BIVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIVI vs Biotech Stocks
Biovie Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.